EUCTR2005-001013-18-DE进行中（未招募）不适用
Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with Myfortic® and a calcineurin inhibitor (Sandimmun® Optoral or Prograf®) in stable renal transplant patients - APOLLO
ovartis Pharma GmbH0 个研究点开始时间: 2005年11月28日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males or females, aged >18 years
- •2. Maintenance renal transplant recipients at least 6 months and not more than 10 years post-transplantation
- •3. Patients with a serum creatinine < 2,5 mg/dL stable for at least 3 month (according to the investigator)
- •4. Patients receiving Myfortic® (Myfortic dose >/= 720 mg/d) and a CNI (Sandimmun® Optoral or Prograf®) with or without corticosteroids as part of their immunosuppressive regimen for at least 1 month before baseline.
- •5. Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility (see also chapter 8.2).
- •6. Patients who are willing and able to participate in the study and from whom written informed consent has been obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. More than one previous renal transplantation
- •2. Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney
- •3. Patient with proteinuria > 1000 mg/day at baseline
- •4. Patients with hypersensitivity to Certican®, Sandimmun® Optoral, Prograf®, mycophenolic acid, or other components of the formulation (e.g. lactose; see also SPCs)
- •5. Patients who have received an investigational drug within four weeks prior to baseline
- •6. Patients who suffered from severe rejection (more than or equal to BANFF II acute rejection), recurrent acute rejection, or steroid resistant rejection within 3 months of enrollment in this trial (baseline)
- •7. Patients with thrombocytopenia (platelets < 100,000/mm³), with an absolute neutrophil count of < 1,500/mm³ or leucopenia (leucocytes < 4,000/mm³), or hemoglobin < 8 g/dL
- •8. Abnormal physical or laboratory findings of clinical significance within 2 weeks of study inclusion (baseline) which at investigator discretion would interfere with the objectives of the study
- •9. Patients with symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give informed consent
- •10. Patients with a history of malignancy during the last five years, except squamos or basal cell carcinoma of the skin
- •11. Patients who are HIV positive, or Hepatitis C-, or Hepatitis B surface antigen positive
- •12. Evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. AST, ALT or total bilirubin > 3 times UNL)
- •13. Females of childbearing potential who are planning to become pregnant, who are pregnant or lactating and/or who are unwilling to use effective means of contraception (see also chapter 8.2)
- •14. Presence of a clinically significant infection requiring continued therapy, severe diarrhea, active peptic ulcer disease or uncontrolled diabetes mellitus that in the opinion of the investigator would interfere with the appropriate conduct of the study
- •15. Evidence of drug or alcohol abuse
研究者
相似试验
进行中（未招募）
不适用
Multi-center, open-label, prospective, randomized, parallel group study investigating an intensified Myfortic® dosing regimen in comparison to a standard dosing regimen of Myfortic® in combination with Sandimmun® Optoral and Corticosteroids in de novo renal transplant patients - OptiMyzeDe novo renal transplant recipientsMedDRA version: M15Level: LLTClassification code 10023438EUCTR2005-006138-14-DEovartis Pharma GmbH120
进行中（未招募）
1 期
Study to compare a tacrolimus Hexal® based regimen versus a Prograf® based regimen in renal transplantatioEUCTR2011-003795-36-DEovartis Pharma GmbH
进行中（未招募）
1 期
Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose regimen - HERAKLESde novo kidney transplant patientsMedDRA version: 9.1Level: LLTClassification code 10023439Term: Kidney transplant rejectionEUCTR2006-007021-32-DEovartis Pharma GmbH450
进行中（未招募）
1 期
Multicentre, prospective, randomized, open-label, controlled study in de novo kidney transplant recipients to evaluate the impact of cyclosporine or steroid withdrawal at 3 months on graft function, patient and graft survival, and cardiovascular surrogate markers during the first five years after transplantation. - CistcertPreservation of renal function after kidney transplantation in a 5-year, multicentre, prospective, randomized, open-label, controlled studyPatients will be randomized within 24 hours prior to transplantation.?Group 1: Simulect + Neoral + Myfortic + steroid stop at 3 months?Group 2: Simulect + Neoral (decrease dose in one week at mo 3 and replace by Certican) + Myfortic + steroid maintenance.EUCTR2007-005844-26-BEAntwerp University Hospital
进行中（未招募）
3 期
A clinical trial to study the effects of two drugs, R-TPR-026 andAranesp® in patients for correction of anemia due to Chronic Kidney DiseaseCTRI/2013/09/004005Reliance Life sciences Pvt Ltd104